haloperidol has been researched along with Obesity in 30 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 9.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 6.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| "Sixty-three outpatients with schizophrenia who met retrospective and prospective criteria for either residual positive or residual negative symptoms entered a 16-week double-blind, parallel-groups comparison of olanzapine and haloperidol." | 5.11 | Olanzapine treatment of residual positive and negative symptoms. ( Ball, MP; Buchanan, RW; Carpenter, WT; Gold, JM; Kirkpatrick, B; McMahon, RP; Weiner, E, 2005) |
| " This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol)." | 5.11 | Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. ( Ascher-Svanum, H; Kinon, BJ; Stensland, M; Zhao, Z, 2005) |
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 5.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol." | 5.09 | Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999) |
| " This reveals that the atypical antipsychotics are most likely to induce weight gain, in particular clozapine and olanzapine." | 4.82 | [Psychotropics and weight gain]. ( Bryois, Ch; Sahli, Ch, 2004) |
| " The influence of a classical antipsychotic (haloperidol) was compared to that of two atypical antipsychotics, one known to favor weight gain (olanzapine), the other not (ziprasidone)." | 3.74 | Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. ( Carpéné, C; Daviaud, D; de Beaurepaire, R; Even, PC; Minet-Ringuet, J; Prévot, D; Quignard-Boulange, A; Tomé, D; Valet, P; Visentin, V, 2007) |
| "5 and 2 mg of olanzapine, but not lower doses, increase body weight and subcutaneous fat deposition." | 3.73 | A model for antipsychotic-induced obesity in the male rat. ( de Beaurepaire, R; Even, PC; Lacroix, M; Minet-Ringuet, J; Tomé, D, 2006) |
| " To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis." | 3.73 | Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006) |
| " In a first genome scan on obesity under antipsychotics in SZ and BP, we analyzed 21 multigenerational kindreds (508 family members) including several patients treated for a minimum of 3 years mainly with haloperidol or chlopromazine." | 3.72 | A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. ( Bouchard, RH; Chagnon, YC; Emond, C; Maziade, M; Mérette, C; Roy, MA, 2004) |
| " This diabetes insipidus is reversible, non-progressive, unrelated to plasma level, and distinct in attack from lithium-induced hypothyroidism, which may occur at low dosage but is also usually of late onset and reversible or treatable with thyroxine while lithium is continued." | 3.65 | Blood levels and management of lithium treatment. ( Crammer, JL; Crane, G; Rosser, RM, 1974) |
| "Obesity is highly prevalent among patients treated with atypical antipsychotics for schizophrenia." | 2.73 | Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. ( Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S, 2007) |
| " Dosing recommendations however are often based on strategies used in patients with normal body habitus." | 2.66 | Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. ( Barletta, JF; Erstad, BL, 2020) |
| "Haloperidol treatment reduced the voluntary activity and energy expenditure of DR mice and induced insulin resistance in these mice." | 1.37 | Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice. ( de Leeuw van Weenen, JE; Parlevliet, ET; Pijl, H; Romijn, JA; Schröder-van der Elst, JP; van den Berg, SA; Willems van Dijk, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 17 (56.67) | 29.6817 |
| 2010's | 6 (20.00) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erstad, BL | 1 |
| Barletta, JF | 1 |
| Totomoch-Serra, A | 1 |
| Ibarra-Miramon, CB | 1 |
| Manterola, C | 1 |
| Potnuri, AG | 1 |
| Reddy, KP | 1 |
| Suresh, P | 1 |
| Husain, GM | 1 |
| Kazmi, MH | 1 |
| Harishankar, N | 1 |
| Calevro, A | 1 |
| Cotel, MC | 1 |
| Natesan, S | 1 |
| Modo, M | 1 |
| Vernon, AC | 1 |
| Mondelli, V | 1 |
| Robertson, SH | 1 |
| Boomhower, SR | 1 |
| Rasmussen, EB | 1 |
| de Leeuw van Weenen, JE | 2 |
| Auvinen, HE | 1 |
| Parlevliet, ET | 2 |
| Coomans, CP | 1 |
| Schröder-van der Elst, JP | 2 |
| Meijer, OC | 1 |
| Pijl, H | 2 |
| van den Berg, SA | 1 |
| Willems van Dijk, K | 1 |
| Romijn, JA | 1 |
| Hermida, T | 1 |
| Franco, K | 1 |
| Hadi, F | 1 |
| Douyon, K | 1 |
| Chagnon, YC | 1 |
| Mérette, C | 1 |
| Bouchard, RH | 1 |
| Emond, C | 1 |
| Roy, MA | 1 |
| Maziade, M | 1 |
| Sahli, Ch | 1 |
| Bryois, Ch | 1 |
| Buchanan, RW | 1 |
| Ball, MP | 1 |
| Weiner, E | 1 |
| Kirkpatrick, B | 1 |
| Gold, JM | 1 |
| McMahon, RP | 1 |
| Carpenter, WT | 1 |
| Ascher-Svanum, H | 1 |
| Stensland, M | 1 |
| Zhao, Z | 1 |
| Kinon, BJ | 2 |
| Schooler, N | 1 |
| Rabinowitz, J | 1 |
| Davidson, M | 1 |
| Emsley, R | 1 |
| Harvey, PD | 1 |
| Kopala, L | 1 |
| McGorry, PD | 1 |
| Van Hove, I | 1 |
| Eerdekens, M | 1 |
| Swyzen, W | 1 |
| De Smedt, G | 1 |
| Minet-Ringuet, J | 2 |
| Even, PC | 2 |
| Lacroix, M | 1 |
| Tomé, D | 2 |
| de Beaurepaire, R | 2 |
| Guha, P | 1 |
| Roy, K | 1 |
| Sanyal, D | 1 |
| Dasgupta, T | 1 |
| Bhattacharya, K | 1 |
| Lin, EJ | 1 |
| Lee, NJ | 1 |
| Slack, K | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Herzog, H | 1 |
| Sainsbury, A | 1 |
| Valet, P | 1 |
| Carpéné, C | 1 |
| Visentin, V | 1 |
| Prévot, D | 1 |
| Daviaud, D | 1 |
| Quignard-Boulange, A | 1 |
| Kim, B | 1 |
| Kim, SJ | 1 |
| Son, JI | 1 |
| Joo, YH | 1 |
| Saddichha, S | 1 |
| Manjunatha, N | 1 |
| Ameen, S | 1 |
| Akhtar, S | 1 |
| Bernstein, HG | 1 |
| Lendeckel, U | 1 |
| Dobrowolny, H | 1 |
| Stauch, R | 1 |
| Steiner, J | 1 |
| Grecksch, G | 1 |
| Becker, A | 1 |
| Jirikowski, GF | 1 |
| Bogerts, B | 1 |
| Deveaugh-Geiss, J | 1 |
| Pandurangi, A | 1 |
| Wirshing, DA | 1 |
| Wirshing, WC | 1 |
| Kysar, L | 1 |
| Berisford, MA | 1 |
| Goldstein, D | 1 |
| Pashdag, J | 1 |
| Mintz, J | 1 |
| Marder, SR | 1 |
| Jones, B | 1 |
| Basson, BR | 1 |
| Walker, DJ | 1 |
| Crawford, AM | 1 |
| Nakano, H | 1 |
| Lee, SD | 1 |
| Farkas, GA | 1 |
| Gothelf, D | 1 |
| Falk, B | 1 |
| Singer, P | 1 |
| Kairi, M | 1 |
| Phillip, M | 1 |
| Zigel, L | 1 |
| Poraz, I | 1 |
| Frishman, S | 1 |
| Constantini, N | 1 |
| Zalsman, G | 1 |
| Weizman, A | 1 |
| Apter, A | 1 |
| Fuller, AK | 1 |
| Tingle, D | 1 |
| DeVane, CL | 1 |
| Scott, JA | 1 |
| Stewart, RB | 1 |
| Crammer, JL | 1 |
| Rosser, RM | 1 |
| Crane, G | 1 |
| Moon, MK | 1 |
| Mikołajewska, K | 1 |
| Stragierowicz, J | 1 |
| Gromadzińska, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Profile and Anthropometric Changes in Schizophrenia[NCT00534183] | 2,006 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562] | Phase 3 | 20 participants (Actual) | Interventional | 2005-10-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
4 reviews available for haloperidol and Obesity
| Article | Year |
|---|---|
Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.
Topics: Analgesia; Analgesics, Non-Narcotic; Analgesics, Opioid; Benzodiazepines; Critical Illness; Deep Sed | 2020 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripi | 2004 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up | 2001 |
Bisphenol A - Application, sources of exposure and potential risks in infants, children and pregnant women.
Topics: Abortion, Spontaneous; Adult; Benzhydryl Compounds; Birth Weight; Child; Child, Preschool; Drinking; | 2015 |
7 trials available for haloperidol and Obesity
| Article | Year |
|---|---|
Olanzapine treatment of residual positive and negative symptoms.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; | 2005 |
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Diabetes | 2005 |
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Diagnosti | 2007 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I | 1999 |
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Eating; Energy Inta | 2002 |
19 other studies available for haloperidol and Obesity
| Article | Year |
|---|---|
Persistent Hiccups as Main COVID-19 Symptom.
Topics: Cholesterol; Clonazepam; Comorbidity; COVID-19; COVID-19 Drug Treatment; Haloperidol; Hernia, Umbili | 2021 |
Obesity Potentiates the Risk of Drug-Induced Long QT Syndrome - Preliminary Evidence from WNIN/Ob Spontaneously Obese Rat.
Topics: Adiposity; Animals; Antipsychotic Agents; Cardiomegaly; Disease Models, Animal; Female; Haloperidol; | 2021 |
Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue.
Topics: Adipose Tissue; Adiposity; Animals; Antigens, Differentiation; Antipsychotic Agents; Biomarkers; Car | 2018 |
High-fat diet alters weight, caloric intake, and haloperidol sensitivity in the context of effort-based responding.
Topics: Animals; Body Weight; Diet, High-Fat; Dietary Fats; Dopamine; Energy Intake; Feeding Behavior; Halop | 2017 |
Blocking dopamine D2 receptors by haloperidol curtails the beneficial impact of calorie restriction on the metabolic phenotype of high-fat diet induced obese mice.
Topics: Animals; Body Weight; Caloric Restriction; Dietary Fats; Dopamine Antagonists; Dopamine D2 Receptor | 2011 |
Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice.
Topics: Animals; Behavior, Animal; Body Weight; Bromocriptine; Dietary Fats; Dopamine Agonists; Dopamine Ant | 2011 |
Weight gain associated with atypical antipsychotics.
Topics: Adolescent; Benzodiazepines; Child; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Obesity | 2002 |
A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses.
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Chromosomes, Human, Pair 12; Comorbidity; Ge | 2004 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complicati | 2004 |
A model for antipsychotic-induced obesity in the male rat.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Weight; Circadian Rhythm; Die | 2006 |
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli | 2006 |
Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment.
Topics: Adipocytes; Animals; Antipsychotic Agents; Benzodiazepines; Cell Size; Drug Administration Schedule; | 2007 |
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Drug A | 2008 |
Beacon-like/ubiquitin-5-like immunoreactivity is highly expressed in human hypothalamus and increased in haloperidol-treated schizophrenics and a rat model of schizophrenia.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Astrocytes; Cell Line, Tumor; Eye Proteins; Female; | 2008 |
Confusional paranoid psychosis after withdrawal from sympathomimetic amines: two case reports.
Topics: Adult; Aged; Depression; Dextroamphetamine; Diethylpropion; Female; Haloperidol; Humans; Male; Obesi | 1982 |
Dopaminergic modulation of ventilation in obese Zucker rats.
Topics: Animals; Body Temperature; Domperidone; Dopamine; Dopamine Antagonists; Haloperidol; Hypercapnia; Hy | 2002 |
Haloperidol pharmacokinetics following gastric bypass surgery.
Topics: Female; Haloperidol; Humans; Middle Aged; Obesity; Schizophrenia; Stomach | 1986 |
Blood levels and management of lithium treatment.
Topics: Administration, Oral; Adult; Aged; Carbimazole; Delayed-Action Preparations; Dementia; Depression; D | 1974 |
Concern about the Safety of Bisphenol A Substitutes.
Topics: Benzhydryl Compounds; Biological Monitoring; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Epo | 2019 |